Nature Communications (Jun 2023)

Durable contraception in the female domestic cat using viral-vectored delivery of a feline anti-Müllerian hormone transgene

  • Lindsey M. Vansandt,
  • Marie-Charlotte Meinsohn,
  • Philippe Godin,
  • Nicholas Nagykery,
  • Natalie Sicher,
  • Motohiro Kano,
  • Aki Kashiwagi,
  • Maeva Chauvin,
  • Hatice D. Saatcioglu,
  • Julie L. Barnes,
  • Amy G. Miller,
  • Amy K. Thompson,
  • Helen L. Bateman,
  • Elizabeth M. Donelan,
  • Raquel González,
  • Jackie Newsom,
  • Guangping Gao,
  • Patricia K. Donahoe,
  • Dan Wang,
  • William F. Swanson,
  • David Pépin

DOI
https://doi.org/10.1038/s41467-023-38721-0
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Eighty percent of the estimated 600 million domestic cats in the world are free-roaming. These cats typically experience suboptimal welfare and inflict high levels of predation on wildlife. Additionally, euthanasia of healthy animals in overpopulated shelters raises ethical considerations. While surgical sterilization is the mainstay of pet population control, there is a need for efficient, safe, and cost-effective permanent contraception alternatives. Herein, we report evidence that a single intramuscular treatment with an adeno-associated viral vector delivering an anti-Müllerian hormone transgene produces long-term contraception in the domestic cat. Treated females are followed for over two years, during which transgene expression, anti-transgene antibodies, and reproductive hormones are monitored. Mating behavior and reproductive success are measured during two mating studies. Here we show that ectopic expression of anti-Müllerian hormone does not impair sex steroids nor estrous cycling, but prevents breeding-induced ovulation, resulting in safe and durable contraception in the female domestic cat.